287 related articles for article (PubMed ID: 27500242)
21. Spectrum of Epstein-Barr virus-associated diseases in recipients of allogeneic hematopoietic stem cell transplantation.
Xuan L; Jiang X; Sun J; Zhang Y; Huang F; Fan Z; Guo X; Dai M; Liu C; Yu G; Zhang X; Wu M; Huang X; Liu Q
Transplantation; 2013 Sep; 96(6):560-6. PubMed ID: 23842192
[TBL] [Abstract][Full Text] [Related]
22. Successful management of EBV-PTLD in allogeneic bone marrow transplant recipient by virological-immunological monitoring of EBV infection, prompt diagnosis and early treatment.
Chiereghin A; Bertuzzi C; Piccirilli G; Gabrielli L; Squarzoni D; Turello G; Ferioli M; Sessa M; Bonifazi F; Zanoni L; Sabattini E; Lazzarotto T
Transpl Immunol; 2016 Feb; 34():60-4. PubMed ID: 26687013
[TBL] [Abstract][Full Text] [Related]
23. Induction of pre-transplant Epstein-Barr virus (EBV) infection by donor blood transfusion in EBV-seronegative recipients may reduce risk of post-transplant lymphoproliferative disease in adolescent renal transplant patients: report of two cases.
Babel N; Gabdrakhmanova L; Hammer M; Rosenberger C; Oppert M; Volk HD; Reinke P
Transpl Infect Dis; 2005; 7(3-4):133-6. PubMed ID: 16390402
[TBL] [Abstract][Full Text] [Related]
24. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation.
Taylor AL; Marcus R; Bradley JA
Crit Rev Oncol Hematol; 2005 Oct; 56(1):155-67. PubMed ID: 15979320
[TBL] [Abstract][Full Text] [Related]
25. Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center.
Knight JS; Tsodikov A; Cibrik DM; Ross CW; Kaminski MS; Blayney DW
J Clin Oncol; 2009 Jul; 27(20):3354-62. PubMed ID: 19451438
[TBL] [Abstract][Full Text] [Related]
26. Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
Trappe R; Oertel S; Leblond V; Mollee P; Sender M; Reinke P; Neuhaus R; Lehmkuhl H; Horst HA; Salles G; Morschhauser F; Jaccard A; Lamy T; Leithäuser M; Zimmermann H; Anagnostopoulos I; Raphael M; Riess H; Choquet S; ;
Lancet Oncol; 2012 Feb; 13(2):196-206. PubMed ID: 22173060
[TBL] [Abstract][Full Text] [Related]
27. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder.
Davis CL; Harrison KL; McVicar JP; Forg PJ; Bronner MP; Marsh CL
Clin Transplant; 1995 Feb; 9(1):53-9. PubMed ID: 7742583
[TBL] [Abstract][Full Text] [Related]
28. Targeted monitoring of patients at high risk of post-transplant lymphoproliferative disease by quantitative Epstein-Barr virus polymerase chain reaction.
Omar H; Hägglund H; Gustafsson-Jernberg A; LeBlanc K; Mattsson J; Remberger M; Ringdén O; Sparrelid E; Sundin M; Winiarski J; Yun Z; Ljungman P
Transpl Infect Dis; 2009 Oct; 11(5):393-9. PubMed ID: 19497070
[TBL] [Abstract][Full Text] [Related]
29. Epstein-Barr virus-associated post-transplantation lymphoproliferative disorder: potential treatments and implications for nursing practice.
Jiménez S
Clin J Oncol Nurs; 2015 Feb; 19(1):94-8. PubMed ID: 25689655
[TBL] [Abstract][Full Text] [Related]
30. Epstein-Barr Virus-Negative Diffuse Large B-Cell Post-transplant Lymphoma in an Epstein-Barr Virus-Positive Recipient.
Lee C; Vincentelli H; Visuri J; Knight S; Ploeg R
Cureus; 2021 Sep; 13(9):e18134. PubMed ID: 34567913
[TBL] [Abstract][Full Text] [Related]
31. Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease.
Smets F; Latinne D; Bazin H; Reding R; Otte JB; Buts JP; Sokal EM
Transplantation; 2002 May; 73(10):1603-10. PubMed ID: 12042647
[TBL] [Abstract][Full Text] [Related]
32. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
Mentzer SJ; Perrine SP; Faller DV
Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
[TBL] [Abstract][Full Text] [Related]
33. Post-transplantation lymphoproliferative disorder in the Epstein-Barr virus-naïve lung transplant recipient.
Aris RM; Maia DM; Neuringer IP; Gott K; Kiley S; Gertis K; Handy J
Am J Respir Crit Care Med; 1996 Dec; 154(6 Pt 1):1712-7. PubMed ID: 8970360
[TBL] [Abstract][Full Text] [Related]
34. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression.
Newell KA; Alonso EM; Whitington PF; Bruce DS; Millis JM; Piper JB; Woodle ES; Kelly SM; Koeppen H; Hart J; Rubin CM; Thistlethwaite JR
Transplantation; 1996 Aug; 62(3):370-5. PubMed ID: 8779685
[TBL] [Abstract][Full Text] [Related]
35. Post-Transplant Lymphoproliferative Diseases in Pediatric Kidney Allograft Recipients with Epstein-Barr Virus Viremia.
Hyun H; Park E; Cho M; Min SI; Ha J; Kang HJ; Shin HY; Ha IS; Cheong HI; Ahn YH; Kang HG
J Korean Med Sci; 2019 Aug; 34(30):e203. PubMed ID: 31373185
[TBL] [Abstract][Full Text] [Related]
36. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease.
Green M; Cacciarelli TV; Mazariegos GV; Sigurdsson L; Qu L; Rowe DT; Reyes J
Transplantation; 1998 Dec; 66(12):1641-4. PubMed ID: 9884252
[TBL] [Abstract][Full Text] [Related]
37. Tumor origin and CD20 expression in posttransplant lymphoproliferative disorder occurring in solid organ transplant recipients: implications for immune-based therapy.
Gulley ML; Swinnen LJ; Plaisance KT; Schnell C; Grogan TM; Schneider BG;
Transplantation; 2003 Sep; 76(6):959-64. PubMed ID: 14508361
[TBL] [Abstract][Full Text] [Related]
38. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
[TBL] [Abstract][Full Text] [Related]
39. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1. Cancer risk after renal transplantation. Post-transplant lymphoproliferative disease (PTLD): prevention and treatment.
EBPG Expert Group on Renal Transplantation
Nephrol Dial Transplant; 2002; 17 Suppl 4():31-3, 35-6. PubMed ID: 12091638
[TBL] [Abstract][Full Text] [Related]
40. Probable posttransplant lymphoproliferative disorder after pediatric living donor liver transplantation: Is a biopsy still needed?
Matsumura M; Miyagi S; Tokodai K; Kashiwadate T; Fujio A; Miyazawa K; Sasaki K; Saito Y; Kanai N; Unno M; Kamei T
Clin Case Rep; 2022 Nov; 10(11):e6454. PubMed ID: 36348984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]